Expanded Access to Navitoclax

Sponsor
AbbVie
Study ID
NCT03592576
Status
No Longer Available

Conditions

  • Acute Lymphocytic Leukemia (ALL)
  • Lymphoblastic Lymphoma
  • Myelofibrosis

Eligibility Criteria

Sex
All
Age
4 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Navitoclax — DRUG
    Tablet, Oral
  • Venetoclax — DRUG
    Tablet, Oral

Study Details

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Key Dates

Status verified
May 2024

Related Studies